VIEW POINT



PHARMACOVIGILANCE AND AI: ENHANCING DRUG SAFETY WITH AUTOMATION LEVERAGING ARTIFICIAL INTELLIGENCE FOR EFFECTIVE DRUG MONITORING AND REGULATORY COMPLIANCE



1. Introduction to Pharmacovigilance (PV)

Definition

Pharmacovigilance (PV) involves the **monitoring**, **detection**, **assessment**, **and prevention** of adverse effects or any other drug-related problems. It ensures that medicines remain **safe**, **effective**, **and compliant** with global regulatory frameworks.

Importance

PV plays a critical role in patient safety and regulatory adherence. Several well-known examples highlight its impact:



Valsartan contamination with NDMA (a carcinogen) led to global recalls and stringent regulatory measures after PV investigations. Nimesulide restrictions for children under 12 due to PV-reported adverse effects like GI bleeding, ulcers, and clotting.



Challenges in Pharmacovigilance

PV plays a critical role in patient safety and regulatory adherence. Several well-known examples highlight its impact:



2. Al in Pharmacovigilance: Transforming Drug Safety Monitoring

Why AI?

Al provides a scalable, efficient, and intelligent approach to drug safety monitoring, addressing industry pain points:



Natural Language Processing (NLP): Extracts AEs from unstructured reports, clinical notes, and social media. Machine Learning (ML): Identifies risk patterns and prioritizes cases based on severity. Robotic Process Automation (RPA): Automates case processing workflows (e.g., ICSR submissions).

Chatbots & Virtual Assistants: Handles initial patient or HCP reports and pre-triage events.

3. Al powered anomaly detection approach: Infosys Al solution

Context & Industry Challenges: Pharmaceutical firms face a rapidly growing volume of **multi-channel safety data**. The existing **manual approach to anomaly detection** is:



Infosys proposes a Gen AI & Agent AI powered anomaly detection framework to streamline PV processes.

- Automated anomaly detection across AEs, PII, and technical complaint.
- Al powered summarization: Generate structured reports for regulatory submissions.
- PII Anonymization: Ensures compliance with maintaining traceability for internal audits.
- **Proactive risk monitoring:** A flags early patterns warning to prevent escalations.

Process Overview for detecting anomalies from multi-modal data sources - Text, Audio, Images, etc.



4. Strategic Differentiators & Future Roadmap

Key Differentiators



Conclusion

Pharmacovigilance is undergoing a transformational shift with Al-powered automation. Generative AI, NLP, and ML are revolutionizing anomaly detection, case processing, and regulatory reporting. Gen AI-based anomaly classification and summarization framework enhances efficiency, accuracy, and compliance, positioning pharmaceutical companies for next-generation drug safety and regulatory excellence.

* Al in PV is no longer an option—it's a necessity for future-ready pharmacovigilance.

About the Authors



Jayadhar Gundu

(Consultant) at IC-LS

Jayadhar Gundu bringing a unique blend of business acumen and technical expertise drawn from over 7 years of experience across diverse sectors. With a robust background in life sciences consulting and the manufacturing domain, he has delivered transformative solutions in supply chain management. His proficiency in process improvement has led to significant operational gains and enhanced performance for clients. As a responsible AI practitioner he is committed to ethical AI deployment, ensuring that AI technologies are used responsibly and effectively to benefit the life sciences industry.



Sapna Bhardwaj

(Consultant) IC LS

Sapna is a seasoned life sciences consultant with over nine years of experience in R&D, Project and Quality Management, Data Analysis, and Computer System Validation (CSV). She has successfully led projects in safety and quality, driving continuous process improvements to enhance client performance. Passionate about innovation, she is eager to explore AI technologies and their responsible application in the life sciences industry.



For more information, contact askus@infosys.com

© 2025 Infosys Limited, Bengaluru, India. All Rights Reserved. Infosys believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Infosys acknowledges the proprietary rights of other companies to the trademarks, product names and such other intellectual property rights mentioned in this document. Except as expressly permitted, neither this documentation nor any part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, printing, photocopying, recording or otherwise, without the prior permission of Infosys Limited and / or any named intellectual property rights holders under this document.

